| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Gonzales E et al. | Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy. | 2009 | Gastroenterology | pmid:19622360 |
| Masserini B et al. | The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma. | 2009 | Eur. J. Endocrinol. | pmid:18835977 |
| Corradi LS et al. | Increased androgen receptor and remodeling in the prostatic stroma after the inhibition of 5-alpha reductase and aromatase in gerbil ventral prostate. | 2009 | Microsc. Res. Tech. | pmid:19484778 |
| Liu J et al. | Anti-androgenic activity of fatty acids. | 2009 | Chem. Biodivers. | pmid:19353546 |
| Reismann P et al. | Pharmacological options for treatment of hyperandrogenic disorders. | 2009 | Mini Rev Med Chem | pmid:19689407 |
| Pollegioni L et al. | Cholesterol oxidase: biotechnological applications. | 2009 | FEBS J. | pmid:19843167 |
| Rosłoniec KZ et al. | Cytochrome P450 125 (CYP125) catalyses C26-hydroxylation to initiate sterol side-chain degradation in Rhodococcus jostii RHA1. | 2009 | Mol. Microbiol. | pmid:19843222 |
| Yehuda R et al. | Enduring effects of severe developmental adversity, including nutritional deprivation, on cortisol metabolism in aging Holocaust survivors. | 2009 | J Psychiatr Res | pmid:19162277 |
| Osborne DM and Frye CA | Estrogen increases latencies to seizures and levels of 5alpha-pregnan-3alpha-ol-20-one in hippocampus of wild-type, but not 5alpha-reductase knockout, mice. | 2009 | Epilepsy Behav | pmid:19782646 |
| Kotłowska A et al. | The urinary steroid profile in patients diagnosed with adrenal incidentaloma. | 2009 | Clin. Biochem. | pmid:19297679 |
| Lemus AE et al. | Bioconversion of norethisterone, a progesterone receptor agonist into estrogen receptor agonists in osteoblastic cells. | 2009 | J. Endocrinol. | pmid:19008332 |
| Zoccolella S et al. | Current and emerging treatments for amyotrophic lateral sclerosis. | 2009 | Neuropsychiatr Dis Treat | pmid:19966906 |
| Schmidt LJ et al. | Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts. | 2009 | Prostate | pmid:19676081 |
| Miller J and Tarter TH | Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. | 2009 | Clin Interv Aging | pmid:19554096 |
| Abe M et al. | Isolation and pharmacological characterization of fatty acids from saw palmetto extract. | 2009 | Anal Sci | pmid:19359798 |
| Fitzpatrick JM et al. | Prostate cancer: a serious disease suitable for prevention. | 2009 | BJU Int. | pmid:19302133 |
| Fujii T et al. | Efficient biotransformations using Escherichia coli with tolC acrAB mutations expressing cytochrome P450 genes. | 2009 | Biosci. Biotechnol. Biochem. | pmid:19352031 |
| Lintker KB et al. | A comparison of the packing behavior of egg phosphatidylcholine with cholesterol and biogenically related sterols in Langmuir monolayer films. | 2009 | Chem. Phys. Lipids | pmid:19524563 |
| Biggio G et al. | GABA(A) receptor function and gene expression during pregnancy and postpartum. | 2009 | Int. Rev. Neurobiol. | pmid:19607962 |
| Yawno T et al. | Role of neurosteroids in regulating cell death and proliferation in the late gestation fetal brain. | 2009 | Neuroscience | pmid:19591903 |
| Taplin ME et al. | Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. | 2009 | Clin. Cancer Res. | pmid:19887483 |
| Bhasin S and Storer TW | Anabolic applications of androgens for functional limitations associated with aging and chronic illness. | 2009 | Front Horm Res | pmid:19011296 |
| Shimoda H et al. | The hypocholesterolemic effects of Cistanche tubulosa extract, a Chinese traditional crude medicine, in mice. | 2009 | Am. J. Chin. Med. | pmid:19938221 |
| Xiao WH et al. | Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. | 2009 | Pain | pmid:19833436 |
| Le Lay S et al. | Caveolin-1-dependent and -independent membrane domains. | 2009 | J. Lipid Res. | pmid:19074371 |
| Vassiliadi DA et al. | Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. | 2009 | J. Clin. Endocrinol. Metab. | pmid:19567518 |
| Perlmutter JD and Sachs JN | Inhibiting lateral domain formation in lipid bilayers: simulations of alternative steroid headgroup chemistries. | 2009 | J. Am. Chem. Soc. | pmid:19860442 |
| Juan Escudero JU et al. | [Green light laser efficacy in patients with prostatic hyperplasia treatment with 5-alpha reductase inhibitors]. | 2009 | Actas Urol Esp | pmid:19925759 |
| Frankel PH and Twardowski P | Guideline for 5-alpha-reductase inhibitors in the prevention of prostate cancer is premature. | 2009 | J. Clin. Oncol. | pmid:19738114 |
| Colciago A et al. | Chronic treatment with polychlorinated biphenyls (PCB) during pregnancy and lactation in the rat Part 2: Effects on reproductive parameters, on sex behavior, on memory retention and on hypothalamic expression of aromatase and 5alpha-reductases in the offspring. | 2009 | Toxicol. Appl. Pharmacol. | pmid:19464308 |
| Cabeza M et al. | Novel C-6 substituted and unsubstituted pregnane derivatives as 5alpha-reductase inhibitors and their effect on hamster flank organs diameter size. | 2009 | Steroids | pmid:19406144 |
| Kuo HC and Liu HT | Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. | 2009 | Scand. J. Urol. Nephrol. | pmid:19308807 |
| Castro BM et al. | Cholesterol-rich fluid membranes solubilize ceramide domains: implications for the structure and dynamics of mammalian intracellular and plasma membranes. | 2009 | J. Biol. Chem. | pmid:19520848 |
| Droller MJ | A guideline for discussion and some thoughts. | 2009 | J. Urol. | pmid:19249064 |
| Kramer BS et al. | Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. | 2009 | J. Urol. | pmid:19249063 |
| Jeong YB et al. | Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study. | 2009 | Urology | pmid:19193422 |
| Ueki I et al. | SRD5B1 gene analysis needed for the accurate diagnosis of primary 3-oxo-Delta4-steroid 5beta-reductase deficiency. | 2009 | J. Gastroenterol. Hepatol. | pmid:19175828 |
| Capyk JK et al. | Mycobacterial cytochrome p450 125 (cyp125) catalyzes the terminal hydroxylation of c27 steroids. | 2009 | J. Biol. Chem. | pmid:19846551 |
| Veldhuis JD et al. | Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men. | 2009 | J. Clin. Endocrinol. Metab. | pmid:19088159 |
| Zhou X et al. | High abundance of testosterone and salivary androgen-binding protein in the lateral nasal gland of male mice. | 2009 | J. Steroid Biochem. Mol. Biol. | pmid:19524040 |
| Ditscheid B et al. | Faecal steroid excretion in humans is affected by calcium supplementation and shows gender-specific differences. | 2009 | Eur J Nutr | pmid:19009227 |
| Chiang YR et al. | Cholest-4-en-3-one-delta 1-dehydrogenase, a flavoprotein catalyzing the second step in anoxic cholesterol metabolism. | 2008 | Appl. Environ. Microbiol. | pmid:17993555 |
| Palermo M et al. | Human Delta4-3-oxosteroid 5beta-reductase (AKR1D1) deficiency and steroid metabolism. | 2008 | Steroids | pmid:18243262 |
| Gooren LJ et al. | Decline of plasma 5alpha-dihydrotestosterone (DHT) levels upon testosterone administration to elderly men with subnormal plasma testosterone and high DHT levels. | 2008 | Andrologia | pmid:18811920 |
| Kolasa A et al. | Expression of E-SOD, GPX5 mRNAs and immunoexpression of Cu/ZnSOD in epididymal epithelial cells of finasteride-treated rats. | 2008 | Andrologia | pmid:18811921 |
| Bordet T et al. | Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy. | 2008 | J. Pharmacol. Exp. Ther. | pmid:18492948 |
| Amory JK et al. | The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. | 2008 | J. Urol. | pmid:18423697 |
| Tomlinson JW et al. | Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss. | 2008 | Diabetes | pmid:18340018 |
| Wilt TJ and N'Dow J | Benign prostatic hyperplasia. Part 2--management. | 2008 | BMJ | pmid:18219042 |
| Khan SA | Synthesis, characterization and in vitro antibacterial activity of new steroidal 5-en-3-oxazolo and thiazoloquinoxaline. | 2008 | Eur J Med Chem | pmid:18455270 |
| Carneiro MM et al. | Androgen receptor and 5alpha-reductase are expressed in pelvic endometriosis. | 2008 | BJOG | pmid:17983420 |
| Hadziselimovic F and Dessouky N | Differences in testicular development between 5alpha-reductase 2 deficiency and isolated bilateral cryptorchidism. | 2008 | J. Urol. | pmid:18639287 |
| Holzgrabe U and Sinz A | [Alpha blockers and 5-alpha reductase inhibitors]. | 2008 | Pharm Unserer Zeit | pmid:18615868 |
| Golbano JM et al. | Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. | 2008 | Int. J. Oncol. | pmid:18360719 |
| Koltz L and Clarke N | Open to debate. The Motion: all men over the age of 50 should be encouraged to take a 5alpha-reductase inhibitor to prevent prostate cancer. | 2008 | Eur. Urol. | pmid:18308462 |
| Gallegos PJ and Frazee LA | Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. | 2008 | Pharmacotherapy | pmid:18294115 |
| Liu S and Yamauchi H | Different patterns of 5alpha-reductase expression, cellular distribution, and testosterone metabolism in human follicular dermal papilla cells. | 2008 | Biochem. Biophys. Res. Commun. | pmid:18258185 |
| Assinder SJ | Oxytocin increases 5alpha-reductase activity of human prostate epithelial cells, but not stromal cells. | 2008 | Prostate | pmid:18008328 |
| Faucher F et al. | The crystal structure of human Delta4-3-ketosteroid 5beta-reductase defines the functional role of the residues of the catalytic tetrad in the steroid double bond reduction mechanism. | 2008 | Biochemistry | pmid:18624455 |
| Ford MM et al. | Inhibition of 5alpha-reduced steroid biosynthesis impedes acquisition of ethanol drinking in male C57BL/6J mice. | 2008 | Alcohol. Clin. Exp. Res. | pmid:18565155 |
| Tomlinson JW et al. | Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. | 2008 | Diabetes | pmid:18633104 |
| Dixon J et al. | Prolonged human chorionic gonadotrophin stimulation as a tool for investigating and managing undescended testes. | 2007 | Clin. Endocrinol. (Oxf) | pmid:17645564 |
| Thevis M et al. | Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite. | 2007 | Ther Drug Monit | pmid:17417080 |
| Petraki CD and Sfikas CP | Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. | 2007 | Histol. Histopathol. | pmid:17128417 |
| Bordet T et al. | Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. | 2007 | J. Pharmacol. Exp. Ther. | pmid:17496168 |
| Wheeler RE | Is it necessary to cure prostate cancer when it is possible? (Understanding the role of prostate inflammation resolution to prostate cancer evolution). | 2007 | Clin Interv Aging | pmid:18044088 |
| Borst SE et al. | Anabolic effects of testosterone are preserved during inhibition of 5alpha-reductase. | 2007 | Am. J. Physiol. Endocrinol. Metab. | pmid:17488806 |
| Araki M et al. | Decreased efficiency of potassium-titanyl-phosphate laser photoselective vaporization prostatectomy with long-term 5 alpha-reductase inhibition therapy: is it true? | 2007 | Urology | pmid:18068449 |
| Hannemann F et al. | Biocatalytic synthesis of 4-pregnen-20,21-diol-3-one, a selective inhibitor of human 5alpha-reductase type II. | 2007 | J Enzyme Inhib Med Chem | pmid:18035825 |
| Andersson KE | LUTS treatment: future treatment options. | 2007 | Neurourol. Urodyn. | pmid:17696154 |
| Barat P et al. | Effects of gonadectomy on glucocorticoid metabolism in obese Zucker rats. | 2007 | Endocrinology | pmid:17628001 |
| Moinpour CM et al. | Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. | 2007 | J. Natl. Cancer Inst. | pmid:17596576 |
| Lunacek A et al. | Fetal distribution of 5alpha-reductase 1 and 5alpha-reductase 2, and their input on human prostate development. | 2007 | J. Urol. | pmid:17574609 |
| Kibel AS | Optimizing prostate biopsy techniques. | 2007 | J. Urol. | pmid:17509275 |
| Schmidt LJ et al. | Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. | 2007 | Prostate | pmid:17477363 |
| Prayer-Galetti T | Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. | 2007 | Eur. Urol. | pmid:17448594 |
| Yassin AA and Saad F | Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate. | 2007 | Andrologia | pmid:17714216 |
| Cussenot O et al. | Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. | 2007 | Eur. Urol. | pmid:17448593 |
| Maier C | Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. | 2007 | Eur. Urol. | pmid:17448591 |
| Morgentaler A | Re: The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. | 2007 | J. Urol. | pmid:17437855 |
| Chai TC | Treatment of men with lower urinary tract symptoms and overactive bladder. | 2007 | JAMA | pmid:17374808 |
| GarcÃa CI et al. | Differential gene expression during development in two oligodendroglial cell lines overexpressing transferrin: a cDNA array analysis. | 2007 | Dev. Neurosci. | pmid:17119318 |
| Seiffert K et al. | Inhibition of 5alpha-reductase activity in SZ95 sebocytes and HaCaT keratinocytes in vitro. | 2007 | Horm. Metab. Res. | pmid:17326010 |
| Cabeza M et al. | New progesterone derivatives as inhibitors of 5alpha-reductase enzyme and prostate cancer cell growth. | 2006 | J Enzyme Inhib Med Chem | pmid:17059168 |
| Stine KJ et al. | Interaction of the glycoalkaloid tomatine with DMPC and sterol monolayers studied by surface pressure measurements and Brewster angle microscopy. | 2006 | J Phys Chem B | pmid:17078662 |
| Patel S and Mishra BK | Oxidation of cholesterol by a biomimetic oxidant, cetyltrimethylammonium dichromate. | 2006 | J. Org. Chem. | pmid:16626135 |
| Sánchez P et al. | Effects of testosterone on brain mRNA levels of steroid 5alpha-reductase isozymes in early postnatal life of rat. | 2006 | Neurochem. Int. | pmid:16828201 |
| Sobel V et al. | Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes. | 2006 | J. Clin. Endocrinol. Metab. | pmid:16735493 |
| Grinthal A and Guidotti G | CD39, NTPDase 1, is attached to the plasma membrane by two transmembrane domains. Why? | 2006 | Purinergic Signal. | pmid:18404478 |
| Motola DL et al. | Identification of ligands for DAF-12 that govern dauer formation and reproduction in C. elegans. | 2006 | Cell | pmid:16529801 |
| Rouquette-Jazdanian AK et al. | Revaluation of the role of cholesterol in stabilizing rafts implicated in T cell receptor signaling. | 2006 | Cell. Signal. | pmid:15925486 |
| Santillo VM and Lowe FC | Treatment of benign prostatic hyperplasia in patients with cardiovascular disease. | 2006 | Drugs Aging | pmid:17067183 |
| Hall MC | The effect of oxysterols, individually and as a representative mixture from food, on in vitro cultured bovine ovarian granulosa cells. | 2006 | Mol. Cell. Biochem. | pmid:16983501 |
| Norg RJ et al. | A decision aid for GPs for the treatment of elderly male patients with lower urinary tract symptoms (LUTS). | 2006 | Fam Pract | pmid:16971394 |
| Ekinci S et al. | Sigmoid colon vaginoplasty in children. | 2006 | Eur J Pediatr Surg | pmid:16909357 |
| Randall VA et al. | New dimensions in Hirsutism. | 2006 | Lasers Med Sci | pmid:16874541 |
| Marks LS et al. | The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. | 2006 | J. Urol. | pmid:16890642 |
| Pitts WR | Re: The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. | 2006 | J. Urol. | pmid:16753453 |
| Frye SV | Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor. | 2006 | Curr Top Med Chem | pmid:16719800 |
| Andriole GL et al. | Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. | 2006 | J. Urol. | pmid:16600723 |
4-Cholesten-3-one
4-Cholesten-3-one is a lipid of Sterol Lipids (ST) class. 4-cholesten-3-one is associated with abnormalities such as Dehydration, Xanthomatosis, Cerebrotendinous, Peripheral Neuropathy, L.mexicana and Xanthoma. The involved functions are known as CYP27A1activity, 25-hydroxycholesterol 7alpha-hydroxylase activity, Biochemical Pathway, Anabolism and Oxidation. 4-cholesten-3-one often locates in Mitochondria, Liver, Body tissue, Hepatic, Mitochondria and Endothelium of artery. The associated genes with 4-Cholesten-3-one are P4HTM gene, tryptones and Regulon. The related lipids are Cholestenones, 7-hydroxy-4-cholesten-3-one, cholest-4-en-3-one, 25-hydroxycholesterol and 24-hydroxycholesterol.
Cross Reference
Introduction
To understand associated biological information of 4-Cholesten-3-one, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 4-Cholesten-3-one?
4-Cholesten-3-one is suspected in Dehydration, Xanthomatosis, Cerebrotendinous, Peripheral Neuropathy, L.mexicana, Xanthoma, Rare Diseases and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Biochem. J. (1)
- J. Biol. Chem. (1)
- J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (1)
- Others (3)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
No disease MeSH terms mapped to the current reference collection.
PubChem Associated disorders and diseases
What pathways are associated with 4-Cholesten-3-one
Lipid pathways are not clear in current pathway databases. We organized associated pathways with 4-Cholesten-3-one through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Related references are published most in these journals:
| Pathway name | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 4-Cholesten-3-one?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Biol. Chem. (2)
- J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (1)
- J. Lipid Res. (1)
- Others (2)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with 4-Cholesten-3-one?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 4-Cholesten-3-one?
Related references are published most in these journals:
- J. Biol. Chem. (2)
- Chem. Biol. Interact. (1)
- J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (1)
- Others (3)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with 4-Cholesten-3-one?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 4-Cholesten-3-one?
There are no associated biomedical information in the current reference collection.